BIO-TECHNE Corp
TECH- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000842023
No open-market purchases or sales by BIO-TECHNE Corp insiders were filed in the last 90 days; 597 institutions reported holding it in 13F filings for Q2 2026, worth $12.3B in total; 3 superinvestors hold it, including Maverick Capital and Weitz Investment Management.
Q4 2021 vs. Q3 2021
How the institutions holding BIO-TECHNE Corp changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Of which not filed for Q4 2021 | Q4 2021 | Change |
|---|---|---|---|---|
| Holders | 567 | 8 | 576 | +17 |
| Shares | 36.8M | 94.1K | 37.0M | +284.3K (+0.8%) |
| Value | $17.8B | $45.6M | $19.1B | +$1.33B (+7.5%) |
8 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so the changes leave them out.
New holders (73)
Institutions that held BIO-TECHNE Corp at the end of Q4 2021 but not at the end of Q3 2021.
Sold out (56)
Institutions that held BIO-TECHNE Corp at the end of Q3 2021 and filed for Q4 2021 without it.
Not filed for Q4 2021 yet (8)
Institutions that held BIO-TECHNE Corp at the end of Q3 2021 and haven't filed a 13F for Q4 2021. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Marshall Wace North America L.P. | 72,183 | $35.0M |
| B. Metzler seel. Sohn & Co. Holding AG | 19,510 | $9.45M |
| Cardan Capital Partners, LLC | 900 | $436.0K |
| Ameritas Investment Company, LLC | 695 | $337.0K |
| World Asset Management Inc | 654 | $317.0K |
| Berman Capital Advisors, LLC | 128 | $62.0K |
| Heritage Wealth Management, LLC | 32 | $16.0K |
| BBVA USA | 24 | $12.0K |